MCF7/164R-7 Cell Line

A human fulvestrant-resistant breast cancer model used to study acquired endocrine resistance, EGFR signalling, and combination therapies. Save 30% on this cell line this summer. Use code SUM26CELL at checkout.

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society, Denmark
SKU: 152103
Product description: The MCF7/164R-7 cell line is a human breast cancer cell line resistant to fulvestrant (Faslodex), established from the parental MCF7 S0.5 line. The cellular classification is epithelial, and their shape is polygonal. Treatment with the anti-estrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, acquired resistance will inevitably occur also for fulvestrant. This cell line can be used to study the molecular changes associated with fulvestrant resistance, in order to develop next-line therapies that can inhibit or delay the emergence of resistance.
Alternate name: MCF7/164R-7; 164R-7
Gender: Female
Production details: The MCF7/164R-7 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 164,384 in 100 nM concentration, see Lykkesfeldt et al 1995. The MCF7/164R-7 cells are also resistant to the pure steroidal antiestrogen fulvestrant (ICI 182,780) and can be maintained continuously in growth medium with 100 nM fulvestrant.
Additional notes: Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level compared to the parental MCF7/S0.5 cell line. The MCF7/164R-7 cells do not express progesterone receptor. The MCF7/164R-7 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells. Passage 430 (AL2678, AL2679)
Cellosaurus ID: CVCL_1D39
Parental cell line: MCF7 S0.5
Disease: Cancer
Cat. #: 152103
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Breast
Gender: Female
Model: Tumour line
Cancer Types In Detail: Breast cancer;Fulvestrant resistant
Primary citation: Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159.
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
Temperature: 37° C
Atmosphere: 5% CO2
References:

Thrane et al. 2015. Oncogene. 34:4199–4210. PMID: 25362855.

Marchand et al. 2012. J Manipulative Physiol Ther. 35(5):372-380. PMID: 22627100.

Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-613. PMID: 19697122.

Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-275. PMID: 18409071.

Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.

Larsen et al. 1997. Int J Cancer. 72(6):1129-1136. PMID: 9378550.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159

Images

View Gallery
MCF7 164R-7 Cell Line. Early log phase. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

Citations And Reviews

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.